MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) is expanding its artificial intelligence voice diagnostics platform with the addition of fatigue detection technology, according to a press release issued by the company. The AI-powered fatigue recognition system analyzes voice patterns and is intended to be added as a commercial feature to the company’s Edge AI Intoxication Detection Kiosks. The technology targets high-risk industries including aviation, road transport, and mining, where operator fatigue poses significant safety risks.
The fatigue detection module complements MindBio’s broader voice-based diagnostics platform designed to identify intoxication and neurological impairment. Initial commercial testing of the kiosk platform is expected in late second quarter 2026. The company’s AI prediction model uses over 50 million data points to predict alcohol intoxication with remarkable accuracy, just by using the human voice. The company is developing an enterprise platform that includes Edge-AI kiosks integrating bespoke hardware and software for the detection of drug and alcohol intoxication using the human voice and AI in a range of enterprise environments.
This development is significant because fatigue-related incidents in high-risk industries can lead to catastrophic outcomes, including loss of life and substantial economic costs. By leveraging voice analysis, MindBio’s technology offers a non-invasive, rapid, and scalable method to detect impairment or fatigue in workers. This could potentially transform safety protocols in sectors such as mining, aviation, and construction, where current methods often rely on subjective assessments or time-consuming testing.
The integration of fatigue detection into the existing kiosk platform also demonstrates MindBio’s commitment to building a comprehensive voice-based diagnostic suite. The company’s AI model, trained on tens of millions of data points, has already shown high accuracy in predicting alcohol intoxication. Extending this capability to fatigue detection could provide employers with a unified tool for monitoring multiple forms of impairment.
Market analysts view this expansion as a strategic move to address a broader safety market. The global fatigue detection market is expected to grow significantly as industries seek automated solutions to enhance workplace safety. MindBio’s technology, if successful in commercial trials, could position the company as a leader in voice-based health and safety diagnostics. The company’s focus on edge AI ensures that data processing occurs locally, addressing privacy concerns and enabling real-time results without relying on cloud connectivity.
The press release also notes that the latest news and updates relating to MBQIF are available in the company’s newsroom at https://nnw.fm/MBQIF. For more information about MindBio Therapeutics, the full press release can be accessed at https://nnw.fm/WWgcb.
